Synthesis and evaluation of the activity of the peptide isolated from the venom of the Lycosa erythrognatha spider on tumor development: In silico and in vitro study
molecular modeling, glioblastoma, mass spectrometry
Glioblastoma (GBM) is one of the most prevalent brain tumors. Your current therapy options include surgical resection followed by radiation and chemotherapy. For chemotherapy, temozolomide still serves as the main chemotherapy drug for GBM patients. However, patients remain with a low survival rate. In this context, new molecules have been studied for treatment, such as peptides isolated from animal venoms for their pharmacological properties, such as antitumor and antimicrobial activity, suggesting that they are promising candidates for the development of new drugs, especially for the treatment of GBM. In this study, the characterization of the Ly-1 peptide, isolated from the venom of the Lycosa erythrognatha spider, began. With the bioinformatics analysis it was possible to confirm in silico that the Ly-1 peptide is an amphipathic peptide and has an affinity for phospholipid membranes. Molecular modeling of the Ly-1 peptide performed in the Modeller program produced good statistical results, indicating that the model is plausible. The results obtained demonstrate that Ly-1 may be a promising peptide with antitumor activity.